Company news
Keros Therapeutics, Inc. (NASDAQ:KROS) news
Keros Therapeutics, Inc. news releases on 6ix. Latest, Sep 29, 2026: Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
Press releases & updates
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
September 28, 2026
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
September 28, 2026
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
September 8, 2026
Keros Therapeutics Reports Second Quarter 2026 Financial Results
August 3, 2026
Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
July 30, 2026
Keros Therapeutics Appoints Anne Prener to its Board of Directors
June 25, 2026
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
June 1, 2026
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
May 13, 2026
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS
March 8, 2026
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
March 4, 2026
Keros Therapeutics Appoints Charles Newton to its Board of Directors
February 26, 2026
Keros Therapeutics Announces Final Results of Tender Offer
November 19, 2025
Keros Therapeutics Announces Preliminary Results of Tender Offer
November 18, 2025
Keros Therapeutics Reports Third Quarter 2025 Financial Results
November 4, 2025
Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares
October 19, 2025
Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
October 14, 2025
Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting
September 7, 2025
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
August 27, 2025
Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy
August 19, 2025
Keros Therapeutics Reports Second Quarter 2025 Financial Results
August 5, 2025
Keros to Exclusively Prioritize the Clinical Advancement of KER-065
August 5, 2025
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept
July 16, 2025
Keros Announces Return of $375 Million in Excess Capital to Stockholders
June 8, 2025
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference
June 5, 2025
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring
May 28, 2025
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros’ Director Nominees
May 26, 2025
ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth
May 21, 2025
Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value
May 18, 2025
Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference
May 11, 2025
Keros Reinforces Commitment to Maximizing Stockholder Value
May 7, 2025
Keros Therapeutics Reports Recent First Quarter 2025 Financial Results
May 5, 2025
Keros Therapeutics Announces Review of Strategic Alternatives
April 9, 2025
Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers
March 30, 2025
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
February 25, 2025
Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
January 29, 2025
Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept
January 20, 2025
Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial
January 14, 2025
Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial
December 11, 2024
Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition
December 8, 2024
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
December 2, 2024
Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept
December 2, 2024
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
November 5, 2024
Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
November 5, 2024
Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition
November 4, 2024
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer
October 15, 2024
Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference
September 11, 2024
Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial
September 2, 2024
Keros Therapeutics Reports Second Quarter 2024 Financial Results
August 6, 2024
Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association
June 16, 2024
Keros Therapeutics Announces Leadership Updates
June 16, 2024